© 2002 by Heart
JournalScan
JournalScan
| The first 150 words of the full text of this article appear below. |
Ischaemic heart disease
Folate as a way to reduce in-stent restenosis
Plasma homocysteine has been recognised as an important cardiovascular risk factor. Several groups have found a link between homocysteine concentrations and angiographic restenosis within stents. A trial of 553 patients assigned to lowering of homocysteine with B12 (400 µg/day), folate (1 mg/day), and pyridoxine (10 mg/day) versus placebo suggests benefit at one year. The combined end point of death/myocardial infarction/repeat revascularisation showed a relative risk (RR) of 0.68 on treatment (15.4% v 22.8%; p = 0.03), primarily caused by a reduced rate of target lesion revascularisation (9.9% v 16.0%, RR 0.62, 95% confidence interval (CI) 0.40 to 0.97; p = 0.03).
Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss heart study: a randomized controlled trial. JAMA 2002;
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
